Shares of Novo Nordisk A/S (NVO) plummeted 5.02% in intraday trading on Thursday, following a significant downgrade from HSBC. The global banking giant revised its rating on the Danish pharmaceutical company from Buy to Hold, triggering a sell-off among investors.
HSBC not only downgraded Novo Nordisk but also drastically reduced its price target for the stock. The new target was set at $57, a substantial decrease from the previous target of $102. This adjustment represents a nearly 44% reduction in HSBC's valuation of the company, contributing to the sharp decline in Novo Nordisk's stock price.
The rationale behind HSBC's decision appears to be linked to concerns about Novo Nordisk's position in the obesity market. According to the firm, their previous thesis that Novo would regain obesity market share is no longer supported. This shift in perspective suggests that HSBC analysts have reassessed the company's growth prospects in this key therapeutic area, leading to a more cautious stance on the stock.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。